Health Care/Hospital

Novogene Bolsters Global Presence with Expanded PacBio Revio Fleet, Advancing Long-Read Sequencing Applications

SINGAPORE, Jan. 10, 2024 /PRNewswire/ -- Novogene further expands its long-read sequencing capacity with the acquisition of six additional PacBio Revio sequencers, augmenting its fleet of multi-platforms sequencing technology. This strategic investment underline Novogene's commitment to enhancing...

2024-01-10 10:30 2043

LOTTE BIOLOGICS Announces Songdo Bio Plant Development Plan at JPM Healthcare Conference 2024

* Richard Lee, CEO of LOTTE BIOLOGICS, delivers a keynote speech at the JPM Healthcare Conference for the second consecutive year * Unveils company's bio plant development plan in Songdo to meet clients' needs SEOUL, South Korea, Jan. 9, 2024 /PRNewswire/ -- LOTTE BIOLOGICS (CEO Richard Lee) ...

2024-01-10 08:55 1198

Health Recovery Solutions (HRS) Applauded by Frost & Sullivan for Transforming Remote Care Delivery with Its Clinically Enabled, Patient-centric RPM Solutions

HRS's RPM solutions enhance patient outcomes and satisfaction, optimize hospital bed utilization, improve quality, reduce costs, and curb readmissions across diverse healthcare settings. SAN ANTONIO, Jan. 9, 2024 /PRNewswire/ -- Frost & Sullivan researched the remote patient monitoring (RPM) ind...

2024-01-09 23:00 1197

Last Chance for Animals, Animal Liberation Wave Applaud Historic Victory for Compassion as South Korea Bans Dog Meat

SEOUL, South Korea, Jan. 9, 2024 /PRNewswire/ -- In a monumental step towards a more compassionate and humane society, Last Chance for Animals (LCA) and Animal Liberation Wave (ALW) celebrate the recent decision bySouth Korea to ban dog meat. This historic move underscores a profound shift toward...

2024-01-09 22:15 962

GBI Secures Commercial Manufacturing Contract, Solidifying Leadership in Radiopharmaceutical Manufacturing

PLANTATION, Fla., Jan. 9, 2024 /PRNewswire/ -- GBI BioManufacturing, formerly known as Goodwin Biotechnology, proudly announces the signing of its second Master Supply Agreement (MSA) for commercializing a radioimmunoconjugate product. This milestone not only showcases our commitment to advancing...

2024-01-09 22:00 1094

Toratani Co., Ltd. Unveils Groundbreaking "Virtuous Circulation Pillow and Mattress" with Patented Technology for Enhanced Deep Breathing Experience

New sleeping solutions that facilitate deeper breathing, improve sleep quality, and bring health benefits TOKYO, Jan. 9, 2024 /PRNewswire/ -- Toratani Co., Ltd. (Kahoku City, Ishikawa Prefecture,Japan) has announced the launch of their innovative Toratani Virtuous Circulation Mattress and Pillow...

2024-01-09 21:00 1063

Menarini Silicon Biosystems announces publication of the DETECT III trial results highlighting the potential clinical utility of HER2 testing in circulating tumor cells with CELLSEARCH

Results published by the DETECT study group indicate the relevance of assessing biomarker expression in Circulating Tumor Cells (CTCs) with the minimally invasive liquid biopsy-based CELLSEARCH® platform to optimize treatment strategy and outcome in patients at an advanced stage of their disease....

2024-01-09 18:55 1074

Baopu Development Joins IWBI's WELL for Residential Program

To help catalyze and spur leadership in health and well-being across the residential sector,Baopu Development is participating in a first-of-its-kind program aimed at establishing IWBI's new global standard for healthier and more resilient homes TAIPEI and NEW YORK, Jan. 9, 2024 /PRNewswire/ -- ...

2024-01-09 16:32 1032

TOKIWA PHYTOCHEMICAL CO., LTD. Announces Latest Clinical Study of VENETRON (R) on Menstrual Well-being

SAKURA, Japan, Jan. 9, 2024 /PRNewswire/ -- TOKIWA PHYTOCHEMICAL CO., LTD. (hereinafter "Tokiwa"),Japan, has announced the publication of the latest research on VENETRON (R), extracted from rafuma leaves. The study, titled "Effect of Apocynum venetum Leaf Extract (VENETRON (R)) on Unidentified C...

2024-01-09 15:00 1223

Enhancing Leadership in Gynecology, Asieris Pharmaceuticals Appoints Sophia Cao to Lead the Newly-Established Women's Health Business Unit, Accelerating Strategic Expansion

SHANGHAI, Jan. 8, 2024 /PRNewswire/ -- Asieris Pharmaceuticals (Stock code :688176.SH) has announced its set-up of the Women's Health Business Unit for commercialization. This strategic move is designed to enhance the company's focus on genitourinary diseases and strengthen its position in women'...

2024-01-09 12:25 1274

Abbisko Therapeutic announces that EMA has granted orphan drug designation for its CSF-1R inhibitor Pimicotinib (ABSK021)

SHANGHAI, Jan. 8, 2024 /PRNewswire/ -- On January 9, 2024 (Beijing Time), Abbisko Therapeutics (HKEX code: 02256) announced that its investigational innovative CSF-1R inhibitor pimicotinib(ABSK021) has been granted orphan drug designation(ODD) by the European Medicines Agency (EMA) for the treatm...

2024-01-09 08:30 1075

Innovent Announces the First Phase 3 Clinical Trial of Mazdutide in Chinese Adults with Overweight or Obesity Met the Primary and All Key Secondary Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA

ROCKVILLE, Md. and SUZHOU, China, Jan. 9, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ...

2024-01-09 08:00 3300

GC Cell's Promising AB-201 Cancer Treatment to Begin Phase 1 Trials Using Lunit AI Platform

South Korea's first CAR-NK cell therapy cleared for human trials in Australia and domestically; Cancer Moonshot participant GC Cell partnering with medical AI leader Lunit to collaborate on AB-201 clinical development YONGIN, South Korea and SYDNEY, Jan. 9, 2024 /PRNewswire/ -- GC Cell

2024-01-09 00:00 1378

Novaestiq Unveils Platform of Innovations; Poised to Disrupt the US Aesthetic Market

SOUTHLAKE, Texas, Jan. 8, 2024 /PRNewswire/ -- Novaestiq Corp., a growth-oriented aesthetic and medical dermatological innovations company, focused on delivering a platform of creative solutions to practices and patients, proudly announces its definitive agreement with Croma-Pharma GmbH to be th...

2024-01-08 22:28 1138

WuXi AppTec Triples Peptide Manufacturing Capacity and Launches the New Taixing API Manufacturing Site

Expansion Boosts Solid-Phase Peptide Synthesis Total Reactor Volume to 32,000 Liters in Response to Surging Demand SHANGHAI, Jan. 8, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, b...

2024-01-08 22:00 4554

Akeso to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Share Its Corporate & Innovative Clinical Development Roadmap

HONG KONG, Jan. 8, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso," "we," or the "Company") today announced thatMichelle Xia, Ph.D, the founder, chairwoman, president, and CEO of Akeso, will deliver a keynote speech focusing on the Company's achievements in the development of new bispecific a...

2024-01-08 21:38 1035

YS Biopharma Announces Changes to its Board Committees

GAITHERSBURG, Md., Jan. 8, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseas...

2024-01-08 21:00 1249

Novel Technology Transforms Baldness Treatment Using Beard and Body Hair

LOS ANGELES, Jan. 8, 2024 /PRNewswire/ -- The ongoing puzzle of having lots of body hair but little on the scalp has confounded many dealing with hair loss. A breakthrough emerges with Dr. U Hair and Skin Clinic reports a pioneering study published in the esteemed Dermatologic Surgery journal tit...

2024-01-08 21:00 1151

Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries

* Libtayo (cemiplimab) is a leading PD-1 inhibitor that has shown efficacy in the treatment of certain patients with cutaneous squamous cell carcinoma, advanced basal cell carcinoma, advanced non-small cell lung cancer and advanced cervical cancer, and is approved by regulatory authorities in m...

2024-01-08 20:30 1225

The World's First Clinical Base Editing Therapy for Hemoglobinopathy

CorrectSequence Therapeutics' CS-101 Successfully Cures One Patient of Transfusion-Dependent β-Thalassemia SHANGHAI, Jan. 8, 2024 /PRNewswire/ -- On January 8, 2024, Shanghai,China, CorrectSequence Therapeutics Co., Ltd. ( Correctseq

2024-01-08 19:46 1516
1 ... 45464748495051 ... 808